Delphine Nerbollier Berlin Published on September 26, 2023 at 9:12 p.m. Modified on September 26, 2023 at 11:46 p.m.
The battle is burning between BioNTech and Curevac, the two German biotechnology nuggets highlighted by the Covid-19 pandemic. The first, based in Mainz, in western Germany, achieved a masterstroke by being the first, in 2020, to develop and market a vaccine against Covid-19, with its American partner Pfizer. The second, based in Tübingen, in the south of Germany, has certainly failed to produce such a vaccine but could take its revenge, through legal channels. She has in fact filed a complaint against her competitor for patent infringement. Opened in August in Düsseldorf, the trial continues this Thursday, September 28 and could lead to a decision concerning four patents. A fifth decision could be made in December.
Read also: The messenger RNA war has only just begun
Interested in this item?
Don’t miss any of our content published daily – subscribe now from 9.- CHF for the first month to access all our articles, files, and analyses.
CHECK OFFERS Good reasons to subscribe to Le Temps: Consult all the unlimited content on the site and the mobile application Access the paper edition in digital version before 7 a.m. Benefit from exclusive privileges reserved for subscribers Access the archives
Already a subscriber? To log in
#Messenger #RNA #Curevac #BioNTech #waging #fratricidal #legal #war